Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

124.89 -1.27 (-1.01%)
Streaming Delayed Price Updated: 12:07 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,483,388
Open 123.69
Bid (Size) 124.87 (2)
Ask (Size) 124.89 (1)
Prev. Close 126.16
Today's Range 123.21 - 124.93
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock. 
Via Chartmill
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga

Performance

YTD
+22.31%
+22.31%
1 Month
-3.22%
-3.22%
3 Month
+18.71%
+18.71%
6 Month
+28.18%
+28.18%
1 Year
+48.17%
+48.17%

More News

Read More
3 Biotech Stocks With Skyrocketing Potential: April 2024
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Why Novo Nordisk Topped the Market Today
Via The Motley Fool
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
Via The Motley Fool
MarketBeat Week in Review – 4/15 - 4/19
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
Via InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Powell And The Great Indecision
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.